Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
IBM is ending sales of its Watson programs aimed at drug discovery and development over poor financial returns, according to a report from Stat.
Bardy Diagnostics, developers of a remote cardiac monitoring chest patch, raised $35.5 million to help fund its platform and expand its sales force.
The two remaining U.S. manufacturers of transvaginal surgical mesh have been ordered by the FDA to halt the sale and distribution of those products.
Thermo Fisher Scientific is bringing high-tech upgrades to its real-time PCR instruments it says are designed to improve the user experience.
Researchers in Israel have printed a three-dimensional human heart using bioinks developed from a patient’s own cells.
The companion diagnostic test was launched at a handful of initial laboratories through Qiagen’s Day-One Lab Readiness program.
New surveillance data tracking infection rates in cleaned duodenoscopes found up to 5.4% tested positive for organisms including E. coli or staph.
Ajax Health's raise will be used to help identify potentially disruptive startups toward the ultimate goal of achieving an exit within four years.
The FDA aims to test the capabilities of real-world evidence by trying to predict the results of randomized, controlled trials before completion.
HemoSonics’ point-of-care diagnostic for a patient’s coagulation status works within 15 minutes, to respond to critical bleeding situations.
